IL13RA2 and glioma: Intracavitary (resection-cavity) infusions of first-generation IL13(E13Y)-zetakine CAR T cells were well tolerated in 3 patients, producing transient anti-glioma activity in 2/3, with reduced IL-13Rα2 expression and new tumor necrosis on MRI (no grade ≥3 toxicity).